CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

preview_player
Показать описание
  1. ASCOcancer
  2. cancer
  3. cancer care
  4. health care
  5. oncology
  6. american society of clinical oncology
Рекомендации по теме
CD19- and CD22-Directed 0:02:36

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

Efficacy of bispecific 0:02:37

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies

Bispecific CAR T-cell 0:00:45

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

Fully human anti-CD19 0:02:12

Fully human anti-CD19 and CD22 bispecific tandem CAR-T

Safety and efficacy 0:06:11

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refracto...

Anti-CD22 CAR T-cell 0:01:21

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status

Durability & safety 0:02:16

Durability & safety of CD22-directed CAR T-cells for patients with LBCL progressing on CD19 CAR-...

Anti-CD22 CAR T-cells 0:03:52

Anti-CD22 CAR T-cells shift ALL into complete remission

Humanized versus murinized 0:03:34

Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma

Phase I study 0:02:32

Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALL

CD19 CAR T 0:57:03

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

Exon structure of 0:08:18

Exon structure of CD19 and CD22 mRNA isoforms revealed by long read sequencing - Mukta Asnani

Lymphoma: Overview of 0:06:13

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells

CD19-directed CAR-T in 0:04:26

CD19-directed CAR-T in patients with R/R high-grade lymphoma

Phase I study 0:03:23

Phase I study of CD22 CAR-T therapy in patients with LBCL who have relapsed after CD19 CAR-T therapy

Evaluating post-infusion CAR-Treg 0:01:29

Evaluating post-infusion CAR-Treg cells to identify patients resistant to CD19 CAR-T therapy

Clinical data for 0:02:26

Clinical data for CD19-directed CAR T-cell products in ALL

Overcoming antigen escape 0:01:40

Overcoming antigen escape following CD19-directed CAR-T therapy

CD19 CAR T-cells 0:04:47

CD19 CAR T-cells for adults

ZUMA-3: KTE-X19, an 0:09:22

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymp...

CD19-directed CAR T-cell 0:07:05

CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia

CAR-T therapy in 0:02:43

CAR-T therapy in pediatric and adult ALL

Sequential CD19 and 0:02:44

Sequential CD19 and BCMA CAR-T

BALLI-01 Study: Is 0:02:42

BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?